Ibuprofen

As one of the most widely used non-steroidal anti-inflammatory drugs (NSAIDs) in the world, ibuprofen exerts triple effects of antipyretic, analgesic and anti-inflammatory by reversibly inhibiting the activity of cyclooxygenase (COX) and reducing the synthesis of prostaglandins. It is commonly used in clinical practice to relieve mild to moderate pain (such as headache, arthralgia, toothache, dysmenorrhea) and fever caused by common cold or influenza, with the applicable population covering adults and children over 6 months old. It is a first-line antipyretic and analgesic drug recommended by诊疗 guidelines of many countries, and has become a core category of household standby drugs due to its high safety and definite efficacy.

The global ibuprofen market size maintains a steady growth trend. In 2023, the overall market size exceeded USD 4 billion, among which the API market accounted for approximately 32%. China is the world's largest producer and exporter of ibuprofen API, with its production capacity accounting for nearly 70% of the global total production capacity. The annual production capacity of leading manufacturers all exceeds 1,000 tons, and the supply covers more than 100 countries and regions around the world. After the implementation of the centralized procurement policy, the terminal price of domestic ibuprofen preparations has decreased significantly, and the demand concentration of upstream API has further increased. Leading enterprises occupy the dominant position in the market by virtue of their cost advantages and compliant production capacity.

The original research enterprise of ibuprofen is Boots Company of the United States, and the original research trade name is Advil. The core compound patent expired globally in 1985. At present, the mainstream dosage forms of the original research and approved products include tablets, capsules, suspensions and suppositories, and the common specifications cover 0.2g, 0.4g, 0.6g, suspension 100ml:2g, etc. The original research products have been included in the FDA Reference Listed Drug Catalog and the Chinese *Catalog of Reference Preparations for Chemical Drugs*. According to the domestic API registration platform, more than 30 enterprises have obtained A-status registration numbers for ibuprofen API, and there are more than 600 approval numbers for domestic ibuprofen preparations, achieving independent supply of all dosage forms. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for ibuprofen API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. They can meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can provide stable reference material support for API R&D, quality research and consistency evaluation work.